NYSE:MRK - Merck & Co. Stock Price, Price Target & More

Get Started

$59.09 -0.04 (-0.07 %)

(As of 05/25/2018 04:00 PM ET)

Previous Close$59.09

Today's Range$58.84 - $59.46

52-Week Range$52.83 - $66.41

Volume6.67 million shs

Average Volume9.53 million shs

Market Capitalization$159.43 billion

P/E Ratio14.85

Dividend Yield3.25%

Beta0.76

About Merck & Co. (NYSE:MRK)

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc., AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., and IO Biotech. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNYSE:MRK

CUSIP58933Y10

Webwww.merck.com

Phone908-740-4000

Debt

Debt-to-Equity Ratio0.63

Current Ratio1.42

Quick Ratio1.10

Price-To-Earnings

Trailing P/E Ratio14.85

Forward P/E Ratio13.97

P/E Growth2.25

Sales & Book Value

Annual Sales$40.12 billion

Price / Sales3.97

Cash Flow$5.7092 per share

Price / Cash10.35

Book Value$12.57 per share

Price / Book4.70

Profitability

EPS (Most Recent Fiscal Year)$3.98

Net Income$2.39 billion

Net Margins4.31%

Return on Equity30.93%

Return on Assets12.66%

Miscellaneous

Employees69,000

Outstanding Shares2,696,190,000

Merck & Co. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co.'s stock symbol?

Merck & Co. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co. pay dividends? What is the dividend yield for Merck & Co.?

Merck & Co. announced a quarterly dividend on Tuesday, May 22nd. Shareholders of record on Friday, June 15th will be paid a dividend of $0.48 per share on Monday, July 9th. This represents a $1.92 annualized dividend and a dividend yield of 3.25%. The ex-dividend date is Thursday, June 14th. View Merck & Co.'s Dividend History.

How will Merck & Co.'s stock buyback program work?

Merck & Co. announced that its Board of Directors has authorized a share buyback plan on Saturday, December 2nd 2017, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were Merck & Co.'s earnings last quarter?

Merck & Co. (NYSE:MRK) announced its quarterly earnings results on Tuesday, May, 1st. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $1.00 by $0.05. The firm had revenue of $10.04 billion for the quarter, compared to the consensus estimate of $10.09 billion. Merck & Co. had a net margin of 4.31% and a return on equity of 30.93%. Merck & Co.'s quarterly revenue was up 6.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.88 earnings per share. View Merck & Co.'s Earnings History.

When is Merck & Co.'s next earnings date?

Merck & Co. is scheduled to release their next quarterly earnings announcement on Friday, July, 27th 2018. View Earnings Estimates for Merck & Co..

What guidance has Merck & Co. issued on next quarter's earnings?

Merck & Co. issued an update on its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $4.16-4.28 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.19. The company issued revenue guidance of $41.8-43.0 billion, compared to the consensus revenue estimate of $41.86 billion.

What price target have analysts set for MRK?

18 equities research analysts have issued 12-month price targets for Merck & Co.'s shares. Their predictions range from $56.00 to $72.00. On average, they expect Merck & Co.'s stock price to reach $65.8644 in the next twelve months. View Analyst Ratings for Merck & Co..

Are investors shorting Merck & Co.?

Merck & Co. saw a decline in short interest during the month of April. As of April 30th, there was short interest totalling 20,402,734 shares, a decline of 11.1% from the April 13th total of 22,946,449 shares. Based on an average daily volume of 13,648,624 shares, the short-interest ratio is currently 1.5 days. Approximately 0.8% of the company's shares are sold short.

Who are some of Merck & Co.'s key competitors?

Some companies that are related to Merck & Co. include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Bayer (BAYRY), GlaxoSmithKline (GSK), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Who are Merck & Co.'s key executives?

Merck & Co.'s management team includes the folowing people:

Mr. Kenneth C. Frazier, Chairman, CEO & Pres (Age 63)
Mr. Robert M. Davis, CFO & Exec. VP of Global Services (Age 51)
Dr. Roger M. Perlmutter, Exec. VP & Pres of Merck Research Laboratories (Age 66)
Mr. Adam H. Schechter, Exec. VP & Pres of Global Human Health (Age 53)
Ms. Rita A. Karachun, Principal Accounting Officer, Sr. VP of Fin. & Global Controller (Age 54)

Has Merck & Co. been receiving favorable news coverage?

News coverage about MRK stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Merck & Co. earned a daily sentiment score of 0.11 on Accern's scale. They also gave press coverage about the company an impact score of 46.96 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are Merck & Co.'s major shareholders?

Merck & Co.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.85%), Franklin Resources Inc. (1.82%), Northern Trust Corp (1.24%), Boston Partners (0.55%), Legal & General Group Plc (0.50%) and Barrow Hanley Mewhinney & Strauss LLC (0.47%). Company insiders that own Merck & Co. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co..

Which institutional investors are selling Merck & Co. stock?

MRK stock was sold by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Federated Investors Inc. PA, Northern Trust Corp, Boston Partners, Barrow Hanley Mewhinney & Strauss LLC, Swiss National Bank, Independent Franchise Partners LLP and Legal & General Group Plc. Company insiders that have sold Merck & Co. company stock in the last year include Julie L Gerberding, Michael J Holston, Thomas H Glocer, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co..

Which institutional investors are buying Merck & Co. stock?

MRK stock was purchased by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Pzena Investment Management LLC, Natixis, Manning & Napier Group LLC, Levin Capital Strategies L.P., American Century Companies Inc., Sound Shore Management Inc. CT and Summit Trail Advisors LLC. View Insider Buying and Selling for Merck & Co..

How do I buy shares of Merck & Co.?

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co.'s stock price today?

One share of MRK stock can currently be purchased for approximately $59.09.

How big of a company is Merck & Co.?

Merck & Co. has a market capitalization of $159.43 billion and generates $40.12 billion in revenue each year. The company earns $2.39 billion in net income (profit) each year or $3.98 on an earnings per share basis. Merck & Co. employs 69,000 workers across the globe.

How can I contact Merck & Co.?

Merck & Co.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]

MarketBeat Community Rating for Merck & Co. (MRK)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		612 (Vote Outperform)
Underperform Votes:		637 (Vote Underperform)
Total Votes:		1,249

MarketBeat's community ratings are surveys of what our community members think about Merck & Co. and other stocks. Vote "Outperform" if you believe MRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Merck & Co. (NYSE:MRK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Merck & Co. in the last 12 months. Their average twelve-month price target is $65.8644, suggesting that the stock has a possible upside of 11.46%. The high price target for MRK is $72.00 and the low price target for MRK is $56.00. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Hold
Consensus Rating Score:	2.78	2.78	2.56	2.44
Ratings Breakdown:	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 8 Hold Rating(s) 10 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 8 Hold Rating(s) 9 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$65.8644	$65.8644	$66.1250	$66.20
Price Target Upside:	11.46% upside	10.72% upside	21.22% upside	21.76% upside

Merck & Co. (NYSE:MRK) Consensus Price Target History

Price Target History for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/26/2018	BMO Capital Markets	Boost Price Target	Outperform ➝ Outperform	$65.00 ➝ $70.00	Low
4/25/2018	Deutsche Bank	Reiterated Rating	Hold		Low
4/23/2018	Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$60.15 ➝ $58.83	Low
4/20/2018	Cowen	Reiterated Rating	Hold	$67.00	Low
4/17/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $70.00	Low
4/17/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$59.80 ➝ $63.00	Low
4/13/2018	Jefferies Group	Set Price Target	Hold	$56.00	Low
4/5/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$62.00 ➝ $64.00	Low
3/12/2018	Leerink Swann	Upgrade	Market Perform ➝ Outperform		Low
2/14/2018	Credit Suisse Group	Lower Price Target	Outperform ➝ Outperform	$66.00 ➝ $65.00	Low
2/13/2018	DZ Bank	Upgrade	Hold ➝ Buy		Low
1/16/2018	SunTrust Banks	Upgrade	Hold ➝ Buy	$54.00 ➝ $72.00	High
11/15/2017	Sanford C. Bernstein	Reiterated Rating	Buy	$64.00	N/A
11/1/2017	Berenberg Bank	Reiterated Rating	Hold		N/A
10/30/2017	Citigroup	Upgrade	Buy		N/A
10/30/2017	UBS	Lower Price Target	Buy	$72.00 ➝ $67.00	N/A
10/29/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$70.00	N/A
7/29/2017	Piper Jaffray Companies	Set Price Target	Buy	$70.00	Low
1/13/2017	Bryan, Garnier & Co	Initiated Coverage	Buy		N/A
1/12/2017	Guggenheim	Upgrade	Neutral ➝ Buy	$61.63 ➝ $70.00	N/A
10/27/2016	Argus	Reiterated Rating	Buy	$65.00 ➝ $80.00	N/A

(Data available from 5/26/2016 forward)

Merck & Co. (NYSE:MRK) Earnings History and Estimates Chart

Earnings by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Earnings Estimates

2018 EPS Consensus Estimate: $4.19

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.96	$1.01	$0.99
Q2 2018	2	$1.06	$1.11	$1.09
Q3 2018	2	$1.09	$1.13	$1.11
Q4 2018	2	$0.97	$1.05	$1.01

Merck & Co. (NYSE MRK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
7/27/2018							N/A
5/1/2018	Q1 2018	$0.9980	$1.05	$10.0884 billion	$10.0370 billion	View	N/A
2/2/2018	Q4 2017	$0.94	$0.98	$10.4850 billion	$10.4330 billion	View	Listen
10/27/2017	Q3 2017	$1.03	$1.11	$10.5450 billion	$10.3250 billion	View	N/A
7/28/2017	Q2 17	$0.87	$1.01	$9.7463 billion	$9.93 billion	View	N/A
5/2/2017	Q1 2017	$0.83	$0.88	$9.2539 billion	$9.4340 billion	View	Listen
2/2/2017	Q416	$0.8890	$0.89	$10.22 billion	$10.10 billion	View	Listen
10/25/2016	Q316	$0.99	$1.07	$10.17 billion	$10.50 billion	View	Listen
7/29/2016	Q216	$0.91	$0.93	$9.79 billion	$9.84 billion	View	Listen
5/5/2016	Q116	$0.85	$0.89	$9.45 billion	$9.30 billion	View	N/A
2/3/2016	Q415	$0.91	$0.93	$10.32 billion	$10.22 billion	View	Listen
10/27/2015	Q315	$0.91	$0.96	$10.11 billion	$10.10 billion	View	Listen
7/28/2015	Q215	$0.80	$0.86	$9.81 billion	$9.80 billion	View	Listen
4/28/2015	Q115	$0.75	$0.85	$9.04 billion	$9.40 billion	View	Listen
2/4/2015	Q414	$0.85	$0.87	$10.61 billion	$10.48 billion	View	Listen
10/27/2014	Q314	$0.88	$0.90	$10.66 billion	$10.56 billion	View	Listen
7/29/2014	Q214	$0.81	$0.85	$10.60 billion	$10.93 billion	View	Listen
4/29/2014	Q114	$0.79	$0.88	$10.44 billion	$10.30 billion	View	Listen
2/5/2014	Q413	$0.88	$0.88	$11.39 billion	$11.30 billion	View	Listen
10/28/2013	Q313	$0.88	$0.92	$11.19 billion	$11.03 billion	View	Listen
7/30/2013	Q2 2013	$0.82	$0.84	$11.22 billion	$11.01 billion	View	Listen
5/1/2013	Q1 2013	$0.79	$0.85	$11.09 million	$10.70 million	View	Listen
2/1/2013	Q4 2012	$0.81	$0.83	$11.46 billion	$11.70 billion	View	Listen
10/26/2012	Q312	$0.92	$0.95	$11.60 billion	$11.50 billion	View	N/A
7/27/2012		$1.02	$1.05			View	N/A
4/27/2012		$0.98	$0.99			View	N/A
2/2/2012		$0.95	$0.97			View	N/A
10/28/2011		$0.91	$0.94			View	N/A
7/29/2011		$0.94	$0.95			View	N/A
4/29/2011		$0.84	$0.92			View	N/A
2/3/2011		$0.83	$0.88			View	N/A
10/29/2010	Q3 2010	$0.83	$0.85			View	N/A
7/30/2010	Q2 2010	$0.82	$0.86			View	N/A
5/4/2010	Q1 2010	$0.75	$0.84			View	N/A
2/16/2010	Q4 2009	$0.78	$0.80			View	N/A
10/22/2009	Q3 2009	$0.82	$0.90			View	N/A
7/21/2009	Q2 2009	$0.78	$0.83			View	N/A
4/21/2009	Q1 2009	$0.77	$0.74			View	N/A
2/3/2009	Q4 2008	$0.74	$0.87			View	N/A
10/22/2008	Q3 2008	$0.79	$0.80			View	N/A
7/21/2008	Q2 2008	$0.83	$0.86			View	N/A
4/21/2008	Q1 2008	$0.85	$0.89			View	N/A
1/30/2008	Q4 2007	$0.73	$0.80			View	N/A

(Earnings results data provided by Zacks Investment Research)

Merck & Co. (NYSE:MRK) Dividend Information

Merck & Co. pays an annual dividend of $1.92 per share, with a dividend yield of 3.25%. MRK's next quarterly dividend payment will be made on Monday, July 9. The company has grown its dividend for the last 6 consecutive years and is increasing its dividend by an average of 2.20% each year. Merck & Co. pays out 48.24% of its earnings out as a dividend.

Next Dividend:	7/9/2018
Annual Dividend:	$1.92
Dividend Yield:	3.25%
Dividend Growth:	2.20% (3 Year Average)
Payout Ratio(s):	48.24% (Trailing 12 Months of Earnings) 45.39% (Based on This Year's Estimates) 42.67% (Based on Next Year's Estimates) 33.63% (Based on Cash Flow)
Track Record:	6 Years of Consecutive Dividend Growth
Frequency:	Quarterly Dividend

Dividend Payments by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE:MRK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/22/2018	quarterly	$0.48	3.28%	6/14/2018	6/15/2018	7/9/2018
1/23/2018	quarterly	$0.48	3.52%	3/14/2018	3/15/2018	4/6/2018
11/28/2017	quarterly	$0.48		12/14/2017	12/15/2017	1/8/2018
7/25/2017	quarterly	$0.47		9/14/2017	9/15/2017	10/6/2017
5/23/2017	quarterly	$0.47	2.9%	6/13/2017	6/15/2017	7/10/2017
2/28/2017	quarterly	$0.47		3/13/2017	3/15/2017	4/7/2017
11/22/2016	quarterly	$0.47	3.05%	12/13/2016	12/15/2016	1/9/2017
7/26/2016	quarterly	$0.46	3.14%	9/13/2016	9/15/2016	10/7/2016
5/24/2016	quarterly	$0.46	3.25%	6/13/2016	6/15/2016	7/8/2016
2/23/2016	quarterly	$0.46	3.64%	3/11/2016	3/15/2016	4/7/2016
11/24/2015	quarterly	$0.46	3.43%	12/11/2015	12/15/2015	1/8/2016
7/22/2015	quarterly	$0.45	3.1%	9/11/2015	9/15/2015	10/7/2015
5/26/2015	quarterly	$0.45	3.03%	6/11/2015	6/15/2015	7/8/2015
2/24/2015	quarterly	$0.45	3.05%	3/12/2015	3/16/2015	4/8/2015
11/25/2014	quarterly	$0.45	3.01%	12/11/2014	12/15/2014	1/8/2015
7/23/2014	quarterly	$0.44	3.02%	9/11/2014	9/15/2014	10/7/2014
5/27/2014	quarterly	$0.44	3.12%	6/12/2014	6/16/2014	7/8/2014
2/25/2014	quarterly	$0.44	3.13%	3/13/2014	3/17/2014	4/7/2014
11/26/2013	quarterly	$0.44	3.53%	12/12/2013	12/16/2013	1/8/2014
7/24/2013	quarterly	$0.43	3.57%	9/12/2013	9/16/2013	10/7/2013
5/28/2013	quarterly	$0.43	3.67%	6/13/2013	6/17/2013	7/8/2013
2/26/2013	quarterly	$0.43	4%	3/13/2013	3/15/2013	4/5/2013

(Data available from 1/1/2013 forward)

Merck & Co. (NYSE MRK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.32%
Institutional Ownership Percentage: 73.14%

Insider Trading History for Merck & Co. (NYSE:MRK)

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Merck & Co. (NYSE MRK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2018	Julie L. Gerberding	EVP	Sell	9,972	$59.66	$594,929.52
4/16/2018	Weir Mirian M. Graddick	Insider	Sell	24,000	$58.00	$1,392,000.00
2/9/2018	Wendell P Weeks	Director	Sell	5,000	$53.57	$267,850.00	5,100
1/16/2018	Michael J. Holston	EVP	Sell	12,500	$61.63	$770,375.00
1/16/2018	Weir Mirian M Graddick	Insider	Sell	60,000	$61.63	$3,697,800.00	101,484
1/12/2018	Weir Mirian M Graddick	Insider	Sell	5,000	$58.00	$290,000.00	101,484
11/8/2017	Thomas H Glocer	Director	Sell	5,000	$56.20	$281,000.00
5/12/2017	C Robert Kidder	Director	Sell	5,000	$63.54	$317,700.00	14,317
4/3/2017	Adam H Schechter	EVP	Sell	53,850	$63.48	$3,418,398.00
2/8/2017	Patricia F Russo	Director	Sell	5,000	$64.42	$322,100.00	18,148
2/6/2017	Wendell P Weeks	Director	Sell	5,000	$64.51	$322,550.00	5,100
2/3/2017	Michael J Holston	EVP	Sell	91,959	$63.96	$5,881,697.64	105,559
2/3/2017	Thomas R Cech	Director	Sell	5,000	$63.42	$317,100.00	5,100
11/10/2016	Kenneth C Frazier	Chairman	Sell	140,000	$65.03	$9,104,200.00	514,957
11/7/2016	Julie L Gerberding	EVP	Sell	85,523	$60.02	$5,133,090.46	77,762
11/2/2016	Rochelle B Lazarus	Director	Sell	20,000	$59.06	$1,181,200.00	9,594
10/3/2016	Weir Mirian M Graddick	Insider	Sell	40,800	$62.07	$2,532,456.00	128,973
9/1/2016	Adam H Schechter	EVP	Sell	39,200	$62.61	$2,454,312.00	39,200
8/10/2016	Clark Golestani	EVP	Sell	3,000	$63.03	$189,090.00
8/5/2016	Kenneth C Frazier	Chairman	Sell	392,000	$61.81	$24,229,520.00	760,877
7/5/2016	Kenneth C Frazier	CEO	Sell	60,000	$58.00	$3,480,000.00	554,856
7/5/2016	Weir Mirian M Graddick	Insider	Sell	45,000	$57.99	$2,609,550.00	123,151
7/1/2016	Adam H Schechter	EVP	Sell	50,000	$57.69	$2,884,500.00	50,000
7/1/2016	Weir Mirian M Graddick	Insider	Sell	30,000	$57.49	$1,724,700.00	162,151
5/20/2016	Clark Golestani	EVP	Sell	39,877	$54.79	$2,184,860.83	17,083
4/14/2016	Kenneth C Frazier	CEO	Sell	131,040	$56.11	$7,352,654.40	653,517
11/4/2015	Wendell P. Weeks	Director	Sell	5,000	$55.53	$277,650.00	100
10/29/2015	Adele D. Ambrose	insider	Sell	37,313	$55.08	$2,055,200.04	19,695
10/29/2015	Kenneth C. Frazier	CEO	Sell	18,666	$54.69	$1,020,843.54	438,236
10/28/2015	Peter C. Wendell	Director	Sell	5,000	$54.85	$274,250.00	1,000
5/11/2015	Adam H Schechter	EVP	Sell	10,634	$60.44	$642,718.96
5/8/2015	Julie L Gerberding	EVP	Sell	38,368	$60.99	$2,340,064.32
5/4/2015	Bruce N Kuhlik	Insider	Sell	56,064	$60.20	$3,375,052.80
4/29/2015	Bruce N Kuhlik	Insider	Sell	156,902	$59.82	$9,385,877.64
4/29/2015	Michael J Holston	EVP	Sell	95,624	$59.84	$5,722,140.16
2/18/2015	Kenneth C Frazier	CEO	Sell	5,164	$58.67	$302,971.88
2/11/2015	Willie A Deese	Insider	Sell	135,864	$58.56	$7,956,195.84
2/9/2015	Peter C Wendell	Director	Sell	5,000	$58.76	$293,800.00
1/15/2015	Adam H Schechter	EVP	Sell	74,200	$62.48	$4,636,016.00
1/9/2015	Kenneth C Frazier	CEO	Sell	8,840	$62.47	$552,234.80
12/10/2014	Kenneth C Frazier	CEO	Sell	9,846	$60.00	$590,760.00
12/8/2014	Bruce N Kuhlik	Insider	Sell	50,000	$62.00	$3,100,000.00
11/26/2014	Rochelle B Lazarus	Director	Sell	10,000	$59.63	$596,300.00
11/24/2014	Wendell P Weeks	Director	Sell	5,000	$59.13	$295,650.00
11/10/2014	Kenneth C Frazier	CEO	Sell	10,000	$57.98	$579,800.00
10/10/2014	Kenneth C Frazier	CEO	Sell	9,895	$59.73	$591,028.35
9/10/2014	Kenneth C Frazier	CEO	Sell	9,814	$60.48	$593,550.72
8/25/2014	Adam H Schechter	EVP	Sell	22,000	$59.70	$1,313,400.00
8/11/2014	Kenneth C Frazier	CEO	Sell	10,058	$57.00	$573,306.00
8/4/2014	Adele D Ambrose	Insider	Sell	28,669	$56.64	$1,623,812.16
7/10/2014	Kenneth C Frazier	CEO	Sell	9,987	$58.03	$579,545.61
7/7/2014	Weir Mirian M Graddick	Insider	Sell	180,047	$59.16	$10,651,580.52
6/27/2014	Willie A Deese	Insider	Sell	72,290	$58.26	$4,211,615.40
6/10/2014	Kenneth C Frazier	CEO	Sell	9,985	$58.06	$579,729.10
5/14/2014	Adam Schechter	EVP	Sell	10,527	$55.91	$588,564.57
4/10/2014	Kenneth Frazier	CEO	Sell	10,047	$57.24	$575,090.28	310,494
4/4/2014	Bruce Kuhlik	Insider	Sell	145,225	$56.43	$8,195,046.75	121,845
2/14/2014	Clark Golestani	EVP	Sell	5,990	$55.47	$332,265.30	6,046
2/13/2014	Bridgette Heller	VP	Sell	43,870	$55.04	$2,414,604.80	27,587
2/11/2014	Adam Schechter	EVP	Sell	18,000	$55.61	$1,000,980.00
2/11/2014	John Canan	Insider	Sell	10,000	$55.70	$557,000.00	10,697
2/11/2014	Kenneth Frazier	CEO	Sell	41,520	$54.52	$2,263,670.40	262,829
2/10/2014	Peter Wendell	Director	Sell	5,000	$54.44	$272,200.00	1,000
2/10/2014	Willie Deese	Insider	Sell	50,000	$54.68	$2,734,000.00	106,049
8/7/2013	Willie Deese	Insider	Sell	50,638	$48.55	$2,458,474.90	106,040
5/15/2013	Adele D Ambrose	Insider	Sell	34,208	$46.66	$1,596,145.28
5/13/2013	Bridgette P Heller	VP	Sell	5,404	$46.15	$249,394.60
8/9/2012	Willie A Deese	Insider	Sell	62,324	$44.26	$2,758,460.24

(Data available from 1/1/2013 forward)

Merck & Co. (NYSE MRK) News Headlines

Source:

Date	Headline
	A Brief Overview of Merck’s First-Quarter Performance finance.yahoo.com - May 25 at 4:25 PM
	This Collaboration Is Expected to Boost Merck’s Long-Term Growth finance.yahoo.com - May 25 at 4:25 PM
	Lenvima’s Approval in Japan Is Expected to Drive Merck’s Growth finance.yahoo.com - May 25 at 4:25 PM
	Opdivo May Witness Decline in This Target Patient Population finance.yahoo.com - May 25 at 4:25 PM
	Merck Appears Unstoppable In Treating Front-Line Lung Cancer seekingalpha.com - May 25 at 9:25 AM
	Merck's Keytruda Shows Survival Benefit in Squamous NSCLC finance.yahoo.com - May 24 at 4:27 PM
	Trump Administration Ups Dose Of Shame As TV Drug Ad Policy Idea Moves Forward finance.yahoo.com - May 24 at 9:46 AM
	Boeing, Merck Buoy the Dow Wednesday 247wallst.com - May 23 at 4:24 PM
	Why the world needs more than one Ebola vaccine finance.yahoo.com - May 23 at 4:24 PM
	Pfizer’s Valuation as of May 22 finance.yahoo.com - May 23 at 4:24 PM
	Ebola patients slip out of Congo hospital as medics try to control outbreak finance.yahoo.com - May 23 at 4:24 PM
	Merck's cancer drug Keytruda notches another trial success finance.yahoo.com - May 23 at 4:24 PM
	Merck: KEYTRUDA Shows Improved Survival Benefit In 407 Trial - Quick Facts www.nasdaq.com - May 23 at 9:11 AM
	Merck's Keytruda increased survival in first-line lung cancer study seekingalpha.com - May 23 at 9:11 AM
	Three Ebola patients escape Congo quarantine, medics race to control outbreak finance.yahoo.com - May 23 at 9:11 AM
	Competitive Pressure And Lower Demand Will Likely Weigh On Merck's Anti-Infective Drug Portfolio www.forbes.com - May 22 at 4:24 PM
	Merck Announces Third-Quarter 2018 Dividend finance.yahoo.com - May 22 at 4:24 PM
	Merck & Co. (MRK) Declares $0.48 Quarterly Dividend www.americanbankingnews.com - May 22 at 4:00 PM
	7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All finance.yahoo.com - May 21 at 4:25 PM
	[$$] Ebola Vaccination Begins in Democratic Republic of Congo finance.yahoo.com - May 21 at 4:25 PM
	Factbox - From sterling crises to Brexit, the tests of Bank of England bosses finance.yahoo.com - May 21 at 4:25 PM
	Congo begins giving experimental Ebola vaccine to medics finance.yahoo.com - May 21 at 4:25 PM
	Dispute on eye drop size fails to catch Supreme Court's eye marketbeat.com - May 21 at 9:55 AM
	Congo to begin Ebola vaccinations on Monday - health ministry finance.yahoo.com - May 20 at 9:52 AM
	Gilead Sciences’ Cash Flows, Valuations, and Price Performance finance.yahoo.com - May 17 at 9:46 AM
	Merck & Co. (MRK) EVP Sells $594,929.52 in Stock www.americanbankingnews.com - May 16 at 1:19 PM
	Zacks Investment Research Downgrades Merck & Co. (MRK) to Hold www.americanbankingnews.com - May 16 at 11:04 AM
	Merck & Co. (MRK) Sees Large Decline in Short Interest www.americanbankingnews.com - May 16 at 1:08 AM
	Ebola Vaccine Headed to Congo to Help Contain Outbreak finance.yahoo.com - May 15 at 4:23 PM
	Merck KGaA's sales hit by currency headwinds www.marketwatch.com - May 15 at 10:06 AM
	Merck KGaA sales hurt by currency, China headwinds www.marketwatch.com - May 15 at 10:06 AM
	Merck & Co Inc. (NYSE:MRK) Is Trading At A 31% Discount finance.yahoo.com - May 15 at 10:06 AM
	Bristol-Myers Squibb’s Cash Flows and Valuation Metrics finance.yahoo.com - May 15 at 10:06 AM
	Keytruda Continues To Be The Game Changer For Merck In 2018 seekingalpha.com - May 14 at 10:56 AM
	What's in the Cards for Merck KGaA (MKGAF) in Q1 Earnings? finance.yahoo.com - May 14 at 10:56 AM
	Is Agenus Inc. (AGEN) a Buy? finance.yahoo.com - May 12 at 10:05 AM
	Merck & Co. (MRK) Expected to Post Quarterly Sales of $10.40 Billion www.americanbankingnews.com - May 12 at 2:58 AM
	Merck, Verizon Pace the Dow Friday 247wallst.com - May 11 at 4:33 PM
	Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings? finance.yahoo.com - May 11 at 10:41 AM
	US stock indexes edge higher in early trading; oil down finance.yahoo.com - May 11 at 10:41 AM
	WHO hopes to use Ebola vaccine to stem outbreak in remote area of Congo finance.yahoo.com - May 11 at 10:41 AM
	How Much Upside Potential Does Celgene Offer? finance.yahoo.com - May 10 at 4:25 PM
	$1.04 Earnings Per Share Expected for Merck & Co. (MRK) This Quarter www.americanbankingnews.com - May 10 at 11:20 AM
	How Valeant Pharmaceuticals Performed in 1Q18 finance.yahoo.com - May 9 at 9:35 AM
	A Overview of Merck’s Diabetes Products in 1Q18 finance.yahoo.com - May 9 at 9:35 AM
	Merck and AstraZeneca Announced EMA Approval for Lynparza finance.yahoo.com - May 8 at 4:24 PM
	Merck Wastes No Time Waiting For End Results, Files For Approval Immediately seekingalpha.com - May 8 at 9:33 AM
	MRK :EU Oks LYNPARZA Tablets To Treat Platinum-Sensitive Relapsed Ovarian Cancer www.nasdaq.com - May 8 at 9:33 AM
	Will Elanco’s Top-Line Growth Return in 2018? finance.yahoo.com - May 8 at 9:33 AM
	Alimta: An Emerging Drug to Treat Lung Cancer finance.yahoo.com - May 7 at 4:27 PM

Merck & Co. (NYSE:MRK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Merck & Co. (NYSE:MRK) Income Statement, Balance Sheet and Cash Flow Statement

Merck & Co. (NYSE MRK) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff